NCT07120087 Evaluation of an Online Intervention to Educate Women at High Risk of Breast Cancer on How to Help Reduce Their Risk.
| NCT ID | NCT07120087 |
| Status | Recruiting |
| Phase | — |
| Sponsor | UNICANCER |
| Condition | Breast Cancer |
| Study Type | INTERVENTIONAL |
| Enrollment | 1,508 participants |
| Start Date | 2026-02-19 |
| Primary Completion | 2026-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 1,508 participants in total. It began in 2026-02-19 with a primary completion date of 2026-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Breast cancer remains the most common cancer among women and a major cause of death despite advances in screening and treatment. Current screening programs are not personalized and are experiencing declining participation. A promising strategy for breast cancer control would be to implement risk-based prevention and early screening, targeting individuals at high risk of developing breast cancer, in order to improve chances of cure and reduce the need for more intensive treatments. The MyPeBS study was designed to assess whether personalized breast cancer screening (based on an individual's risk of developing breast cancer) is as effective as, or more effective than, current standard screening. Lifestyle interventions involving changes in diet or physical activity, for example, have been shown to be effective in reducing the risk of developing breast cancer, whether low or high. The MyPeBS study evaluates personalized screening but offers limited information on breast cancer prevention. MyPREV is a project that aims to assess the feasibility and impact of a personalized online program on breast cancer risk reduction measures. This program is offered to women at high risk of developing breast cancer as part of the European MyPeBS screening study. The main objective is to evaluate adherence to a personalized, online breast cancer prevention program focused on lifestyle and its acceptance among women at high or very high risk of developing cancer who participated in the MyPeBS study.
Eligibility Criteria
Inclusion Criteria: 1. Female (whether born female or not) 2. Women aged 40 to 74 years (inclusive) 3. Women who have participated in, or are participating in the MyPeBS study and who fulfilled all the inclusion and non-inclusion criteria for the MyPeBS study. 4. Women able to express their non-opposition to participate in the intervention 5. Women who were assessed as being at high (≥≥1.67% - 5.9%) or very high (≥≥6%) risk of invasive breast cancer at 5 years in the MyPeBS study Exclusion Criteria: 1\. Women who developed a breast cancer during their follow-up in the MyPeBS study
Frequently Asked Questions
Who can join the NCT07120087 clinical trial?
This trial is open to female participants only, aged 40 Years or older, up to 74 Years, studying Breast Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07120087 currently recruiting?
Yes, NCT07120087 is actively recruiting participants. Visit ClinicalTrials.gov or contact UNICANCER to inquire about joining.
Where is the NCT07120087 trial being conducted?
This trial is being conducted at Lyon, France, Villejuif, France, Torino, Italy.
Who is sponsoring the NCT07120087 clinical trial?
NCT07120087 is sponsored by UNICANCER. The trial plans to enroll 1,508 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.